{"nctId":"NCT01103284","briefTitle":"Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults","startDateStruct":{"date":"2010-04"},"conditions":["Type 1 Diabetes Mellitus"],"count":475,"armGroups":[{"label":"DiaPep277","type":"EXPERIMENTAL","interventionNames":["Drug: DiaPep277"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"DiaPep277","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* clinical diagnosis of type 1 diabetes within last 6 months\n* Age 20-45 years\n* fasting basal C-peptide equal or greater than 0.22 nmol/L, lower than 0.8 nmol/L\n* BMI between 17 and 30 at screening\n\nExclusion Criteria:\n\n* Significant disease or condition other than type 1 diabetes\n* Diabetes-related complications\n* Ongoing treatment with immunosuppressive or immunomodulating agents including chronic corticosteroids","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months","description":"Change in Beta-cell function, measured as stimulated C-peptide secretion 0, 2, 6, 10 and 20 minutes post administration \\[area under the curve (AUC), 0-20 minutes\\] at baseline and 24 months, during a glucagon stimulation test (GST). The change in AUC was calculated per patient by subtracting the baseline AUC from the 24 month AUC.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.20","spread":"0.27"},{"groupId":"OG001","value":"-4.83","spread":"0.30"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects That Achieve Good Glycemic Control: HbA1c<7%","description":"The percentage of subjects achieving good glycemic control, i.e. an HbA1c \\<7% at study end (Month 25). If HbA1c was missing at Month 25, but the Month 24 value was available, then the Month 24 value was used to calculate the percentage of subjects with an HbA1c ≤ 7% at study end.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Subjects Requiring a Daily Insulin Dose ≤ 0.5 IU/kg at End of Study","description":"Percentage of subjects requiring a daily insulin dose ≤ 0.5 IU/kg at end of study (25 Months). If insulin dose was missing at Month 25, but the Month 24 value was available, then the Month 24 value was used to calculate the percentage of subjects with a daily insulin dose ≤ 0.5 IU/kg at study end.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Hypoglycemic Events","description":"Total number of days with at least one hypoglycemic event recorded","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1955","spread":null},{"groupId":"OG001","value":"3264","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Number of Days With at Least One Hypoglycemic Event","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":"2.3"},{"groupId":"OG001","value":"35.4","spread":"7.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":236},"commonTop":["Nasopharyngitis","Headache","Injection site pain","Influenza","Upper respiratory tract infection"]}}}